Andere talen Sarepta Therapeutics, Inc.

Aandelen

SRPT

US8036071004

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
115,6 ^USD	-0,80%		-5,90%	+19,90%

21/03	FDA geeft Italfarmaco's medicijn voor zeldzame spierdystrofie groen licht	RE
12/03	Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

REGENXBIO And Sarepta Agree To Stay Litigation Pending Outcome Of Sarepta's IPR Petition	04/04
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - March 29, 2024	01/04
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	29/03
FDA greenlights Italfarmaco's drug for rare muscular dystrophy	21/03
Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program	20/03
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing	12/03
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing	07/03
Sarepta Therapeutics to Present at Upcoming Investor Conferences	04/03
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	01/03
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/03
Sarepta Therapeutics' Regulatory Drug Review Underpins Prospects for Rally, RBC Says	29/02
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program	29/02
Sarepta Therapeutics anuncia convocatoria de solicitudes para el 7.º Route 79 anual, el Programa de Becas de Duchenne	29/02
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market	28/02
Sarepta Therapeutics: Q4 Earnings Snapshot	28/02
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments	28/02
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $396.8M, vs. Street Est of $386.2M	28/02
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 EPS $0.82, vs. Street Est of $0.37	28/02
Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Sarepta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sarepta Therapeutics, Inc.

Aandelen

SRPT

US8036071004

Andere talen

Filters